ImmuCell Corporation (ICCC) Stock Score, Valuation & Financial Research
ImmuCell Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 31/100.
Quick answer for ICCC
ImmuCell Corporation currently has a Wall Street Score of 31/100. The stored market price is $9.61. Its financial score is 26/100. Its valuation score is 0/100. The latest WSS change is +3.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What ImmuCell Corporation does
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Curre
ICCC financial snapshot
- Wall Street Score:
- 31/100
- Current price:
- $9.61
- Market capitalization:
- $86.9M
- Revenue:
- $30.7M
- Net income:
- $787K
- Free cash flow:
- $1.2M
- Cash:
- $8.9M
- Total debt:
- $5.7M
- EPS:
- -0.12
- Financial score:
- 26/100
- Valuation score:
- 0/100
- Revenue score:
- 36/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $1.2M, showing positive cash generation.
- The balance sheet shows $8.9M of cash versus $5.7M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +3.4 points: ICCC increased 3.4 points because Revenue improved by 4.6 points, Asset improved by 3.2 points, Capital improved by 3 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research ICCC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.